STOCK TITAN
  1. Home
  2. Sec-filings
  3. IRMD
  4. [Form 4] IRADIMED CORP Insider Trading Activity

Insider trust tied to IRADIMED (IRMD) CEO sells 7,500 shares under 10b5-1

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

IRADIMED CORP director and CEO-related trust reports routine open-market sales of common stock. The Phillip Susi 2008 Dynasty Trust sold a total of 7,500 shares of IRMD on March 30, 2026 in three transactions at weighted average prices of $94.81, $95.66 and $96.53 per share. After these trades, the Dynasty Trust holds 2,225,000 shares, while additional indirect holdings reported include 162,950 shares in the Roger E. Susi Revocable Trust and 2,062,500 shares in the Matthew Susi 2008 Dynasty Trust. The sales were carried out under a pre-arranged Rule 10b5-1 trading plan, and the reporting person disclaims beneficial ownership of the securities beyond his pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider Susi Roger E.
Role CEO, President, Chairman
Sold 7,500 shs ($713K)
Type Security Shares Price Value
Sale Common Stock 5,848 $94.81 $554K
Sale Common Stock 1,497 $95.66 $143K
Sale Common Stock 155 $96.53 $15K
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 2,226,652 shares (Indirect, By Phillip Susi 2008 Dynasty Trust)
Footnotes (1)
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025. This transaction was executed in multiple trades at prices ranging from $94.36 to $95.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $95.40 to $96.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $96.50 to $97.16. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.
Shares sold 7,500 shares Open-market sales on March 30, 2026
Weighted average sale price 1 $94.81/share First sale tranche on March 30, 2026
Weighted average sale price 2 $95.66/share Second sale tranche on March 30, 2026
Weighted average sale price 3 $96.53/share Third sale tranche on March 30, 2026
Dynasty Trust holdings 2,225,000 shares Phillip Susi 2008 Dynasty Trust after sales
Revocable Trust holdings 162,950 shares Roger E. Susi Revocable Trust holding entry
Second Dynasty Trust holdings 2,062,500 shares Matthew Susi 2008 Dynasty Trust holding entry
Net share change -7,500 shares Net-sell direction from transaction summary
Rule 10b5-1 trading plan regulatory
"sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"The price reported above reflects the weighted average sale price"
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
beneficial ownership regulatory
"The reporting person disclaims beneficial ownership of these securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Section 16 regulatory
"for purposes of Section 16 or for any other purpose"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Susi Roger E.
(Last)(First)(Middle)
C/O IRADIMED CORPORATION
12705 INGENUITY DRIVE
(Street)
ORLANDO FLORIDA 32826
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
XOfficer (give title below)Other (specify below)
CEO, President, Chairman
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock03/30/2026S(1)5,848D$94.81(2)2,226,652IBy Phillip Susi 2008 Dynasty Trust
Common Stock03/30/2026S(1)1,497D$95.66(3)2,225,155IBy Phillip Susi 2008 Dynasty Trust
Common Stock03/30/2026S(1)155D$96.53(4)2,225,000IBy Phillip Susi 2008 Dynasty Trust
Common Stock162,950IBy Roger E. Susi Revocable Trust
Common Stock2,062,500(5)IBy Matthew Susi 2008 Dynasty Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025.
2. This transaction was executed in multiple trades at prices ranging from $94.36 to $95.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3. This transaction was executed in multiple trades at prices ranging from $95.40 to $96.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
4. This transaction was executed in multiple trades at prices ranging from $96.50 to $97.16. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
5. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.
Remarks:
/s/ Roger E. Susi04/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did the IRADIMED (IRMD) Form 4 filed by Roger E. Susi report?

The Form 4 reports that a trust associated with IRADIMED CEO Roger E. Susi sold 7,500 shares of common stock. The transactions were open-market sales executed on March 30, 2026, and were made under a pre-arranged Rule 10b5-1 trading plan.

How many IRADIMED (IRMD) shares were sold and at what prices?

A total of 7,500 IRADIMED common shares were sold across three trades at weighted average prices of $94.81, $95.66 and $96.53. Each trade was executed in multiple lots within disclosed price ranges, with only the weighted averages reported here.

Who actually holds the IRADIMED (IRMD) shares involved in this Form 4?

The reported sales were by the Phillip Susi 2008 Dynasty Trust, an entity associated with Roger E. Susi. Additional indirect holdings were disclosed in the Roger E. Susi Revocable Trust and the Matthew Susi 2008 Dynasty Trust, with the filer disclaiming full beneficial ownership.

How many IRADIMED (IRMD) shares does the selling trust own after the trades?

After the March 30, 2026 trades, the Phillip Susi 2008 Dynasty Trust holds 2,225,000 IRADIMED common shares. Separate lines in the filing also show 162,950 shares held in a revocable trust and 2,062,500 shares in another dynasty trust as indirect holdings.

Were the IRADIMED (IRMD) insider sales discretionary or under a trading plan?

The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2025. Such plans schedule trades in advance, so the timing of these sales reflects the plan’s terms rather than day-to-day trading decisions by the insider.

Does Roger E. Susi claim full beneficial ownership of all reported IRADIMED (IRMD) shares?

No. The filing states that the reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest. This means he does not assert full economic ownership of every share reported in the trusts’ holdings.